Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

Psilocybin therapy is being explored for cancer-related anxiety, depression, and existential distress. Much of the earlier clinical literature has focused on one-to-one therapy models, so there is relatively little detailed description of how group facilitation might work, particularly for people with metastatic cancer. The authors frame group approaches as potentially important because they may increase access, offer peer support, and create different therapeutic mechanisms through shared experience and community. This technical report describes the facilitation model developed for an FDA-approved Phase I/II single-arm, open-label trial in people with metastatic cancer who had moderate or severe anxiety or depression. The paper’s purpose is not to report the full clinical outcomes, but to explain the group retreat model itself and the theoretical basis for its design. The authors position the intervention as a secular ritual-based approach built around preparation, the psilocybin dosing session, and integration.

The report describes the facilitation model used in a Phase I/II clinical trial (NCT05847696) conducted at the University of Washington. Participants had metastatic cancer and no mental health diagnosis before cancer; the extracted text says 88% were receiving anticancer treatment. The broader trial was a single-arm, open-label study designed to identify a safe facilitator-to-participant ratio for a group intervention in which preparation, dosing, and integration were all delivered in a group format. The intervention comprised two virtual preparatory sessions, a 3-day in-person retreat, and two additional virtual integration sessions. During the retreat, day 1 included a third preparation session, day 2 the psilocybin dosing session, and day 3 the first integration session. The psilocybin session took place in a large shared room so that participants could have both individual and collective experiences. Over eight retreats, the number of participants per retreat was gradually increased from five to eight while keeping four core facilitators and two backup facilitators. The facilitation model was grounded in anthropological ideas about ritual and rites of passage. The authors describe three phases: separation, corresponding to preparation; liminal, corresponding to the psilocybin session; and reincorporation, corresponding to integration. The researchers used Council practice for much of the group process, with a talking piece, circle format, reflective listening, and structured prompts. Preparatory work included psychoeducation, discussion of cancer-related experiences, intention-setting, touch preference discussions, and a brief individual safety/suicidality check. During dosing, facilitators moved through the room, offered touch only according to explicit preferences, and supported participants without directing the experience. Integration combined 1:1 storytelling, group sharing, psychoeducation about returning home, and follow-up virtual sessions to support continued meaning-making. Safety procedures included twice-daily facilitator meetings to discuss boundaries, transference, countertransference, and any concerns; a facilitator on call overnight; and a reporting route to the institutional review board. The study was approved by the University of Washington Institutional Review Board. The authors also note that the team received an updated manual before each retreat and training was conducted before each retreat.

The primary trial result described in this report was safety of the facilitator ratio. The trial escalated enrolment across eight retreats from five to eight participants while maintaining four core facilitators plus two backup facilitators. No safety events occurred, including no instance in which more than four participants simultaneously required 1:1 attention. On that basis, the authors state that a ratio of 4 facilitators to 8 participants was safe. The accompanying trial is said to have found exploratory efficacy in symptoms of anxiety and depression, measured with the Hospital Anxiety and Depression Scale. The extracted text reports a statistically and clinically significant reduction after the retreat (p < 0.0001), with effects described as comparable in magnitude to earlier individual-therapy trials. Reductions were maintained to 6 months. The paper states that participant-reported outcomes are reported in the companion article, and that no participant reported feeling they did not receive the support they needed. This technical report also includes qualitative observations from facilitators. They describe the importance of presence, relational sensitivity, and containment, as well as the value of having personal psychedelic experience. Facilitators emphasised non-intervention, witnessing, and maintaining boundaries while supporting participants through intense or ineffable experiences. These quotations are presented as descriptive material rather than as the product of formal qualitative analysis.

The authors interpret their findings as showing that a secular ritual-based, group retreat model for psilocybin therapy can be delivered safely in a cohort of people with metastatic cancer when supported by a cohesive, well-trained facilitator team. They argue that the model works because it treats the intervention as a rite of passage, with distinct functions in preparation, dosing, and integration, while consistently relying on presence, relational sensitivity, and containment. In their view, the ritual frame supports safety, meaning-making, and communal trust without over-directing participants’ experiences. They position the model as distinct from more medicalised approaches that privilege biomedical expertise. Instead, the authors argue for a Western ethical frame grounded in consent, humility, and non-intrusiveness, while also acknowledging that the retreat setting deliberately engages with themes of mortality, renewal, and nature. They also note that the facilitators themselves were affected by participating in the ritual space, describing the work as reciprocal and meaningful. The authors identify several limitations. The trial was small, single-site, single-arm, and open-label, with no concurrent comparison group. They also caution that the meaning of ritual practices may differ across cultures, which limits generalisability. Finally, they note the tension between describing a living, adaptive facilitation practice and representing it within conventional empirical research. They suggest that the model may need modification for other populations and conditions, and they hope it will stimulate more research on group approaches to psychedelic therapy.

The authors conclude that their rite-of-passage facilitation model was safe for a ratio of 4 facilitators to 8 participants with metastatic cancer and that this represents the first FDA-approved clinical trial of a secular ritual-based group facilitation model associated with empirically demonstrated safety and efficacy outcomes. They suggest that the approach may form a new paradigm for studying facilitation models, while also noting that it will likely need adaptation for other conditions or communities.